Critical BREXAFEMME Development from SCYNEXIS!

Jersey City, N.J., November 19, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company developing innovative therapies to overcome and prevent difficult-to-treat and drug-resistant infections, announced the transfer of the BREXAFEMME (ibrexafungerp) New Drug Application (NDA) to GSK.

SCYNEXIS CEO Dr. David Angulo stated, "We are pleased to announce the completion of the transfer of the BREXAFEMME NDA. With this transfer completed, GSK will be able to begin discussions with the U.S. Food and Drug Administration (FDA) regarding the reintroduction of BREXAFEMME for vulvovaginal candidiasis and recurrent vulvovaginal candidiasis." He added, "Additionally, SCYNEXIS anticipates receiving significant non-dilutive capital in the form of net sales milestones and royalties following the reintroduction."

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company developing innovative therapies to prevent and overcome difficult-to-treat infections. The company aims to help millions of patients worldwide. SCYNEXIS is working on its proprietary antifungal platform known as "fungerps," of which ibrexafungerp, the first representative of this new class, has been licensed to GSK. The FDA has approved BREXAFEMME® (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis and to reduce the frequency of recurrent vulvovaginal candidiasis. Other antifungal assets in this new class are in clinical, pre-clinical, and discovery stages, including the compound SCY-247.